Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 1.2% - Time to Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price fell 1.2% on Thursday . The company traded as low as $4.98 and last traded at $5.10. 5,823,527 shares were traded during mid-day trading, a decline of 63% from the average session volume of 15,537,694 shares. The stock had previously closed at $5.16.

Analysts Set New Price Targets

Several brokerages recently weighed in on RXRX. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Needham & Company LLC dropped their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Morgan Stanley reduced their target price on shares of Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating for the company in a research note on Monday, June 16th. Finally, Leerink Partners dropped their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research report on Friday, February 28th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $7.00.

Recursion Pharmaceuticals Stock Up 2.0%

The stock has a 50 day moving average price of $4.90 and a 200 day moving average price of $6.21. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.11 and a current ratio of 4.11. The company has a market capitalization of $2.14 billion, a P/E ratio of -2.97 and a beta of 0.84.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The company had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. During the same quarter in the previous year, the firm earned ($0.39) earnings per share. The firm's revenue was up 7.2% compared to the same quarter last year. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Ensign Peak Advisors Inc increased its holdings in Recursion Pharmaceuticals by 0.3% during the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock worth $2,774,000 after acquiring an additional 1,300 shares during the period. Farther Finance Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after purchasing an additional 1,353 shares during the period. Summit Investment Advisors Inc. raised its position in shares of Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock worth $176,000 after buying an additional 1,875 shares in the last quarter. Clear Creek Financial Management LLC boosted its stake in Recursion Pharmaceuticals by 9.8% during the first quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock valued at $113,000 after buying an additional 1,907 shares during the period. Finally, GAMMA Investing LLC grew its position in Recursion Pharmaceuticals by 39.0% during the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after buying an additional 2,026 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.